SEC Tracker
Get the app
CYDY · XBRL financial data

CytoDyn financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CYDY's year ends in late May)

In millions of dollarsNov 30, 2023Feb 29, 2024May 31, 2024Aug 31, 2024Nov 30, 2024Feb 28, 2025May 31, 2025Aug 31, 2025Nov 30, 2025Feb 28, 2026May 31, 2026Aug 31, 2026
Research and development114*—————————
General and administrative233*2222*2222*2
Operating income (loss)(3)(3)(7)*22(4)(4)(5)*(5)(22)(6)(6)*(7)
Interest income——year only0000*0000*0
Income tax expense (benefit)000*0000*0000*0
Net income (loss)(10)(12)(17)*19(5)(5)(6)*(6)(23)(5)(10)*(20)
Earnings per share, basic USD per share(0.01)(0.01)(0.02)*0.020.000.000.00*0.00(0.02)0.00(0.01)*(0.01)
Earnings per share, diluted USD per share(0.01)(0.01)(0.02)*0.020.000.000.00*0.00(0.02)0.00(0.01)*(0.01)
Weighted average shares, basic millions of shares9599821,013*1,1351,2211,2281,239*1,2531,2611,2751,368*1,382
Weighted average shares, diluted millions of shares9599821,013*1,1981,2211,2281,323*1,2531,2611,2751,368*1,382

Balance sheet

CSV

Fiscal quarters (CYDY's year ends in late May)

In millions of dollarsNov 30, 2023Feb 29, 2024May 31, 2024Aug 31, 2024Nov 30, 2024Feb 28, 2025May 31, 2025Aug 31, 2025Nov 30, 2025Feb 28, 2026May 31, 2026Aug 31, 2026
Cash and cash equivalents0132521161295161216
Inventory——0—————————
Total current assets9101128252118139181419
Right-of-use asset000000000000
Total assets9101128252118139181419
Accounts payable626230141415151414131313
Total current liabilities12312984707171716985505450
Lease liability, non-current0000000———00
Total liabilities124130128113114114114113129123124117
Accumulated deficit(863)(875)(892)(872)(877)(882)(888)(893)(916)(921)(930)(950)
Total stockholders' equity(114)(119)(117)(85)(89)(93)(96)(100)(120)(104)(110)(98)
Total liabilities and equity9101128252118139181419
Common shares outstanding (cover page) millions of shares9809931,2151,2201,2281,2321,2521,2601,2701,3661,3821,470

Cash flows

CSV

Fiscal quarters (CYDY's year ends in late May)

In millions of dollarsNov 30, 2023Feb 29, 2024May 31, 2024Aug 31, 2024Nov 30, 2024Feb 28, 2025May 31, 2025Aug 31, 2025Nov 30, 2025Feb 28, 2026May 31, 2026Aug 31, 2026
Net income (loss)(10)(12)(17)*19(5)(5)(6)*(6)(23)(5)(10)*(20)
Stock-based compensation1*1*0*01*0*1*00*0*1*1
Net cash from operating activities(3)*(2)*(2)*5(4)*(5)*(6)*(2)(4)*(6)*(5)*(8)
Net cash from investing activities——————year only0——year only0
Proceeds from issuing common stock——————————0*—
Net cash from financing activities1*4*3*100*0*1*(0)0*16*1*12
Net change in cash(2)*1*2*15(4)*(5)*(4)*(3)(4)*11*(4)*5

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
CytoDyn16not reported(7.7)1.5B2.1 quarters 10-QAug 31, 2026
Cryoport269491.1*50.6M— 10-QJun 30, 2026
Capricor Therapeutics21not reported(31)*58.1M7.6 quarters 10-QJun 30, 2026
Theravance Biopharma22021(7)*51.9M55.7 quarters 10-QJun 30, 2026
REGENXBIO36108(62)*66.0M1.7 quarters 10-QJun 30, 2026
Zevra Therapeutics1223810*59.5M— 10-QSep 30, 2026
Cronos Group4675324*368.4M— 10-QJun 30, 2026
aTYR PHARMA16not reported(9.4)*98.1M6.1 quarters 10-QJun 30, 2026
CytomX Therapeutics171.4(18)*217.9M18.3 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.